Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CFD | P00746 | 2/20 | 0.58 |
| ▸ | LMNA | P02545 | 1/20 | 0.56 |
| ▸ | ATR | Q13535 | 4/20 | 0.55 |
| ▸ | TAS1R3 | Q7RTX0 | 3/20 | 0.54 |
| ▸ | TAS1R1 | Q7RTX1 | 3/20 | 0.54 |
| ▸ | TAS1R2 | Q8TE23 | 2/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | HTT | P42858 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | PIK3CD | O00329 | 3/20 | 0.52 |
| ▸ | PIK3CA | P42336 | 3/20 | 0.52 |
| ▸ | PIK3CG | P48736 | 3/20 | 0.52 |
| ▸ | PIK3CB | P42338 | 2/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3462527 | 1.00 | CFD (0.58) | CFDLMNAATRTAS1R3TAS1R1 | |
| SCHEMBL3461822 | 0.95 | ATR (0.56) | CFDLMNAATRMEN1KMT2A | |
| SCHEMBL3461621 | 0.95 | ATR (0.56) | CFDLMNAATRMEN1KMT2A | |
| SCHEMBL3461268 | 0.85 | ATR (0.57) | ATRHTTALDH1A1PIK3CDPIK3CA | |
| SCHEMBL3462631 | 0.85 | ATR (0.57) | CFDLMNAATRTAS1R3TAS1R1 | |
| SCHEMBL3460741 | 0.85 | PIK3CD (0.49) | CFDATRPIK3CDPIK3CAPIK3CG | |
| SCHEMBL14237314 | 0.85 | ATR (0.49) | ATRPIK3CDPIK3CAPIK3CGPIK3CB | |
| SCHEMBL3462222 | 0.85 | ATR (0.54) | CFDLMNAATRTAS1R3TAS1R1 | |
| SCHEMBL3461054 | 0.84 | PIK3CD (0.48) | ATRTAS1R3TAS1R1TAS1R2PIK3CD | |
| SCHEMBL3461074 | 0.84 | PIK3CD (0.48) | ATRTAS1R3TAS1R1TAS1R2PIK3CD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1501514-B1 | PROTEIN KINASE MODULATORS AND METHODS OF USE | EXELIXIS INC (US) | 2012-12-19 | — | — | EP | claimed |
| US-20060211709-A1 | Protein kinase modulators and methods of use | EXELIXIS, INC. | 2006-09-21 | — | — | US | claimed |
| EP-1501514-B1 | PROTEIN KINASE MODULATORS AND METHODS OF USE | EXELIXIS INC (US) | 2012-12-19 | — | — | EP | disclosed |
| US-7704995-B2 | Protein kinase modulators and methods of use | EXELIXIS, INC. (US) | 2010-04-27 | — | — | US | disclosed |
| US-20060211709-A1 | Protein kinase modulators and methods of use | EXELIXIS, INC. | 2006-09-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060211709-A1 | Protein kinase modulators and methods of use | GRK2, MAP4K2, MAPKAPK2 | CFD 4879/4885LMNA 3773/4885ATR 556/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.